Advances in ICIs Therapy after TKIs Resistance in Patients with EGFR Mutant NSCLC: A Review

Advances in ICIs Therapy after TKIs Resistance in Patients with EGFR Mutant NSCLC: A Review

The follow-up treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation after drug resistance to EGFR-tyrosine kinase inhibitors (TKIs) have become a hotspot and difficulty at present. Immune checkpoint inhibitors (ICIs) therapy is a...

Full description

Bibliographic Details
Main Authors: Ran CHEN, Chang JIANG, Li MA, Shucai ZHANG
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2022-08-01
Series:Chinese Journal of Lung Cancer
Subjects:
egfr mutations
egfr-tkis resistance
lung neoplasms
immune checkpoint inhibitors
immunotherapy
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.37

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.37

Similar Items